Paul Tudor Jones Ligand Pharmaceuticals Inc Transaction History

Tudor Investment Corp Et Al

$26.8 Billion
Q3 2024

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$65.67 - $77.08 $283,825 - $333,139	-4,322 Reduced 43.46%	5,622 $414,000
Q4 2022 Feb 14, 2023	BUY	$61.72 - $96.74 $613,743 - $961,982	9,944 New	9,944 $664,000
Q1 2022 May 16, 2022	SELL	$94.99 - $151.56 $314,701 - $502,118	-3,313 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$127.69 - $165.85 $423,036 - $549,461	3,313 New	3,313 $512,000
Q2 2021 Aug 16, 2021	SELL	$113.03 - $155.64 $376,728 - $518,748	-3,333 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$99.52 - $215.83 $1.08 Million - $2.33 Million	-10,805 Reduced 76.43%	3,333 $508,000
Q4 2020 Feb 16, 2021	BUY	$80.55 - $106.05 $704,570 - $927,619	8,747 Added 162.25%	14,138 $1.41 Million
Q3 2020 Nov 16, 2020	BUY	$89.56 - $126.72 $482,817 - $683,147	5,391 New	5,391 $514,000
Q1 2020 May 15, 2020	SELL	$63.37 - $107.88 $366,722 - $624,301	-5,787 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$96.94 - $113.59 $334,539 - $391,999	3,451 Added 147.73%	5,787 $604,000
Q3 2019 Nov 14, 2019	SELL	$86.25 - $120.16 $1.31 Million - $1.83 Million	-15,223 Reduced 86.7%	2,336 $233,000
Q2 2019 Aug 14, 2019	BUY	$107.38 - $129.34 $662,749 - $798,286	6,172 Added 54.2%	17,559 $2 Million
Q1 2019 May 15, 2019	SELL	$105.93 - $142.47 $2.02 Million - $2.71 Million	-19,045 Reduced 62.58%	11,387 $1.43 Million
Q4 2018 Feb 14, 2019	BUY	$128.36 - $272.13 $3.91 Million - $8.28 Million	30,432 New	30,432 $4.13 Million
Q3 2018 Nov 14, 2018	SELL	$211.18 - $274.49 $1.12 Million - $1.46 Million	-5,324 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$150.77 - $207.98 $560,713 - $773,477	3,719 Added 231.71%	5,324 $1.1 Million
Q1 2018 May 15, 2018	BUY	$138.63 - $182.62 $222,501 - $293,105	1,605 New	1,605 $265,000

Others Institutions Holding LGND

# of Institutions

257

Shares Held

18.2M

Call Options Held

26.8K

Put Options Held

9.3K

View Full List

About LIGAND PHARMACEUTICALS INC

Ticker LGND
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,882,800
Market Cap $2.01B
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...

More about LGND

Track Paul Tudor Jones's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.

Account